Elaine Moore writes,
With the increasing costs of specialized drugs, some insurance companies are refusing to pay for drugs prescribed for off-label conditions …
Health policy analysts caution that the benefits off-label drugs offer in conditions for which other drugs have failed will be seriously compromised by these new insurance regulations.
Furthermore, off-label drugs such as naltrexone, which is relatively inexpensive at less than $100 per month, would be put in the same (unapproved for payment) category as Genetech’s Avastin (bevacizumab), which typically costs $4,400 per month. Avastin is approved for lung and colorectal cancers, but not for brain tumors because of limited evidence validating efficacy despite promising results in patients.
Related Posts
-
Will we have to hit bottom before we reform our healthcare system?
-
What is prescription drug insurance, anyway?
-
Just how insured ARE you? Prescription drug co-pays are on the rise
-
Merck and insurance companies at cross-purposes over Gardasil
-
Drug safety: No more excuses
-
Florida Times-Union credits eDrugSearch.com in editorial
Subscribe in a reader
2nd Annual Global Healthcare Blogger Survey Reminder…
As readers of this blog may be aware, my firm Envision Solutions and Trusted.MD Network are currently fielding the second global survey of healthcare bloggers. Since the launch of the poll in August, more than 110 bloggers have taken the……